{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:31:32Z","timestamp":1787592692710,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ductal carcinoma in situ (DCIS) is not life threatening unless it transitions into invasive breast cancer (IBC). However, although breast cancer cell exposure to matrix stiffening in vitro phenotypically mimics the DCIS to IBC switch, the molecular changes driving this switch remains unclear. Here, breast cancer cell kinome activity profiling suggested matrix stiffness-upregulation of 53 kinases, among which 16 kinases were also regulated by integrin \u03b21. Functional validation identified matrix stiffness-activation of inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) and mitogen-activated protein kinase 8 (MAPK8) signaling as critical for the stiffness-driven IBC phenotype, including for cell proliferation. The IKBKE-inhibitor Amlexanox, clinically utilized for aphthous ulcers, as well as the MAPK8 inhibitor JNK-IN-8, reinstalled the DCIS-like phenotype of breast cancer cells on high matrix stiffness. This suggests that IKBKE and\/or MAPK8 inhibitors could enhance the arsenal of treatments to prevent or treat breast cancer.<\/jats:p>","DOI":"10.1186\/s12964-025-02276-y","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T15:32:40Z","timestamp":1749051160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Matrix stiffness-induced IKBKE and MAPK8 signaling drives a phenotypic switch from DCIS to invasive breast cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Feifei","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"G\u00f6ransson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Olofsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Vogiatzakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anagha","family":"Acharekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Str\u00f6mblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"3","key":"2276_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2276_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","volume":"5","author":"O Yersal","year":"2014","unstructured":"Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412\u201324.","journal-title":"World J Clin Oncol"},{"issue":"6 Suppl","key":"2276_CR3","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1002\/1097-0142(197706)39:6<2772::AID-CNCR2820390665>3.0.CO;2-K","volume":"39","author":"S Shapiro","year":"1977","unstructured":"Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer. 1977;39(6 Suppl):2772\u201382.","journal-title":"Cancer"},{"issue":"8433","key":"2276_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(85)92204-4","volume":"1","author":"L Tab\u00e1r","year":"1985","unstructured":"Tab\u00e1r L, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the breast Cancer screening working group of the Swedish National board of health and welfare. Lancet. 1985;1(8433):829\u201332.","journal-title":"Lancet"},{"issue":"12","key":"2276_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jama.1996.03530360023033","volume":"275","author":"VL Ernster","year":"1996","unstructured":"Ernster VL, et al. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996;275(12):913\u20138.","journal-title":"JAMA"},{"issue":"4","key":"2276_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41416-019-0478-6","volume":"121","author":"M van Seijen","year":"2019","unstructured":"van Seijen M, et al. Ductal carcinoma in situ: to treat or not to treat, that is the question. Br J Cancer. 2019;121(4):285\u201392.","journal-title":"Br J Cancer"},{"issue":"5","key":"2276_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s13402-011-0043-7","volume":"34","author":"CB Moelans","year":"2011","unstructured":"Moelans CB, et al. Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Cell Oncol (Dordr). 2011;34(5):475\u201382.","journal-title":"Cell Oncol (Dordr)"},{"issue":"4","key":"2276_CR8","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.celrep.2016.06.051","volume":"16","author":"R Lesurf","year":"2016","unstructured":"Lesurf R, et al. Molecular features of Subtype-Specific progression from ductal carcinoma in situ to invasive breast Cancer. Cell Rep. 2016;16(4):1166\u201379.","journal-title":"Cell Rep"},{"issue":"6","key":"2276_CR9","doi-asserted-by":"publisher","first-page":"e100488","DOI":"10.1371\/journal.pone.0100488","volume":"9","author":"D Pape-Zambito","year":"2014","unstructured":"Pape-Zambito D, et al. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients. PLoS ONE. 2014;9(6):e100488.","journal-title":"PLoS ONE"},{"issue":"10","key":"2276_CR10","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1073\/pnas.0931261100","volume":"100","author":"XJ Ma","year":"2003","unstructured":"Ma XJ, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A. 2003;100(10):5974\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2276_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41392-024-01779-3","volume":"9","author":"J Wang","year":"2024","unstructured":"Wang J, et al. Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance. Signal Transduct Target Ther. 2024;9(1):83.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2276_CR12","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1186\/bcr2222","volume":"11","author":"XJ Ma","year":"2009","unstructured":"Ma XJ, et al. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009;11(1):R7.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"2276_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cell.2021.12.023","volume":"185","author":"T Risom","year":"2022","unstructured":"Risom T, et al. Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. Cell. 2022;185(2):299\u2013e31018.","journal-title":"Cell"},{"issue":"1","key":"2276_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1741-7015-4-38","volume":"4","author":"PP Provenzano","year":"2006","unstructured":"Provenzano PP, et al. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med. 2006;4(1):38.","journal-title":"BMC Med"},{"issue":"3","key":"2276_CR15","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.ajpath.2010.11.076","volume":"178","author":"MW Conklin","year":"2011","unstructured":"Conklin MW, et al. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol. 2011;178(3):1221\u201332.","journal-title":"Am J Pathol"},{"issue":"1","key":"2276_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12916-021-02146-7","volume":"19","author":"G Xi","year":"2021","unstructured":"Xi G, et al. Computer-assisted quantification of tumor-associated collagen signatures to improve the prognosis prediction of breast cancer. BMC Med. 2021;19(1):273.","journal-title":"BMC Med"},{"issue":"10","key":"2276_CR17","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1039\/c5ib00040h","volume":"7","author":"I Acerbi","year":"2015","unstructured":"Acerbi I, et al. Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb). 2015;7(10):1120\u201334.","journal-title":"Integr Biol (Camb)"},{"issue":"3","key":"2276_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ccr.2005.08.010","volume":"8","author":"MJ Paszek","year":"2005","unstructured":"Paszek MJ, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005;8(3):241\u201354.","journal-title":"Cancer Cell"},{"issue":"3","key":"2276_CR19","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1002\/jcb.27681","volume":"120","author":"M Najafi","year":"2019","unstructured":"Najafi M, Farhood B, Mortezaee K. Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J Cell Biochem. 2019;120(3):2782\u201390.","journal-title":"J Cell Biochem"},{"issue":"2","key":"2276_CR20","doi-asserted-by":"publisher","first-page":"188356","DOI":"10.1016\/j.bbcan.2020.188356","volume":"1873","author":"B Piersma","year":"2020","unstructured":"Piersma B, Hayward MK, Weaver VM. Fibrosis and cancer: A strained relationship. Biochim Biophys Acta Rev Cancer. 2020;1873(2):188356.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2276_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.semcdb.2017.07.027","volume":"71","author":"KA Jansen","year":"2017","unstructured":"Jansen KA, Atherton P, Ballestrem C. Mechanotransduction at the cell-matrix interface. Semin Cell Dev Biol. 2017;71:75\u201383.","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"2276_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bph.14195","volume":"176","author":"JF Hastings","year":"2019","unstructured":"Hastings JF, et al. The extracellular matrix as a key regulator of intracellular signalling networks. Br J Pharmacol. 2019;176(1):82\u201392.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2276_CR23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/jcmm.13452","volume":"22","author":"AN Gargalionis","year":"2018","unstructured":"Gargalionis AN, Basdra EK, Papavassiliou AG. Mechanosignalling in tumour progression. J Cell Mol Med. 2018;22(2):704\u20135.","journal-title":"J Cell Mol Med"},{"key":"2276_CR24","doi-asserted-by":"publisher","first-page":"102208","DOI":"10.1016\/j.ceb.2023.102208","volume":"83","author":"KM Young","year":"2023","unstructured":"Young KM, Reinhart-King CA. Cellular mechanosignaling for sensing and transducing matrix rigidity. Curr Opin Cell Biol. 2023;83:102208.","journal-title":"Curr Opin Cell Biol"},{"key":"2276_CR25","doi-asserted-by":"publisher","first-page":"650453","DOI":"10.3389\/fonc.2021.650453","volume":"11","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, et al. Extracellular matrix: emerging roles and potential therapeutic targets for breast Cancer. Front Oncol. 2021;11:650453.","journal-title":"Front Oncol"},{"key":"2276_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bbrc.2023.03.001","volume":"654","author":"S G\u00f6ransson","year":"2023","unstructured":"G\u00f6ransson S, et al. An extracellular matrix stiffness-induced breast cancer cell transcriptome resembles the transition from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC). Biochem Biophys Res Commun. 2023;654:73\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"2276_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1023\/A:1006461422273","volume":"65","author":"SJ Santner","year":"2001","unstructured":"Santner SJ, et al. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat. 2001;65(2):101\u201310.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"2276_CR28","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ijc.11491","volume":"107","author":"PA Kenny","year":"2003","unstructured":"Kenny PA, Bissell MJ. Tumor reversion: correction of malignant behavior by microenvironmental cues. Int J Cancer. 2003;107(5):688\u201395.","journal-title":"Int J Cancer"},{"issue":"5","key":"2276_CR29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","volume":"139","author":"KR Levental","year":"2009","unstructured":"Levental KR, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139(5):891\u2013906.","journal-title":"Cell"},{"issue":"1","key":"2276_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1083\/jcb.137.1.231","volume":"137","author":"VM Weaver","year":"1997","unstructured":"Weaver VM, et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol. 1997;137(1):231\u201345.","journal-title":"J Cell Biol"},{"issue":"14","key":"2276_CR31","doi-asserted-by":"publisher","first-page":"5987","DOI":"10.1158\/0008-5472.CAN-08-3660","volume":"69","author":"AH Sikkema","year":"2009","unstructured":"Sikkema AH, et al. Kinome profiling in pediatric brain tumors as a new approach for target discovery. Cancer Res. 2009;69(14):5987\u201395.","journal-title":"Cancer Res"},{"issue":"2","key":"2276_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrc2544","volume":"9","author":"DT Butcher","year":"2009","unstructured":"Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat Rev Cancer. 2009;9(2):108\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"2276_CR33","doi-asserted-by":"publisher","first-page":"e26182","DOI":"10.1371\/journal.pone.0026182","volume":"6","author":"AM Pereira","year":"2011","unstructured":"Pereira AM, et al. Integrin-dependent activation of the JNK signaling pathway by mechanical stress. PLoS ONE. 2011;6(12):e26182.","journal-title":"PLoS ONE"},{"key":"2276_CR34","doi-asserted-by":"crossref","unstructured":"Rigiracciolo DC et al. Focal adhesion kinase fine Tunes multifaced signals toward breast Cancer progression. Cancers (Basel), 2021. 13(4).","DOI":"10.3390\/cancers13040645"},{"issue":"6","key":"2276_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/intbio\/zyaa012","volume":"12","author":"SC Allen","year":"2020","unstructured":"Allen SC, et al. Dynamic extracellular matrix stiffening induces a phenotypic transformation and a migratory shift in epithelial cells. Integr Biol (Camb). 2020;12(6):161\u201374.","journal-title":"Integr Biol (Camb)"},{"issue":"6","key":"2276_CR36","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.cell.2007.03.052","volume":"129","author":"JS Boehm","year":"2007","unstructured":"Boehm JS, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007;129(6):1065\u201379.","journal-title":"Cell"},{"issue":"1","key":"2276_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cam4.2678","volume":"9","author":"M Yin","year":"2020","unstructured":"Yin M, Wang X, Lu J. Advances in IKBKE as a potential target for cancer therapy. Cancer Med. 2020;9(1):247\u201358.","journal-title":"Cancer Med"},{"issue":"9","key":"2276_CR38","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2165\/00044011-200525090-00001","volume":"25","author":"J Bell","year":"2005","unstructured":"Bell J. Amlexanox for the treatment of recurrent aphthous ulcers. Clin Drug Investig. 2005;25(9):555\u201366.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"2276_CR39","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000234292","volume":"82","author":"H Makino","year":"1987","unstructured":"Makino H, et al. Mechanism of action of an antiallergic agent, amlexanox (AA-673), in inhibiting Histamine release from mast cells. Acceleration of cAMP generation and Inhibition of phosphodiesterase. Int Arch Allergy Appl Immunol. 1987;82(1):66\u201371.","journal-title":"Int Arch Allergy Appl Immunol"},{"issue":"28","key":"2276_CR40","doi-asserted-by":"publisher","first-page":"10544","DOI":"10.1073\/pnas.0603499103","volume":"103","author":"T Sakurai","year":"2006","unstructured":"Sakurai T, et al. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A. 2006;103(28):10544\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2276_CR41","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1172\/JCI37156","volume":"118","author":"L Hui","year":"2008","unstructured":"Hui L, et al. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest. 2008;118(12):3943\u201353.","journal-title":"J Clin Invest"},{"issue":"6","key":"2276_CR42","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1101\/gad.1989311","volume":"25","author":"M Das","year":"2011","unstructured":"Das M, et al. The role of JNK in the development of hepatocellular carcinoma. Genes Dev. 2011;25(6):634\u201345.","journal-title":"Genes Dev"},{"key":"2276_CR43","doi-asserted-by":"crossref","unstructured":"Tam SY, Law HK. JNK in tumor microenvironment: present findings and challenges in clinical translation. Cancers (Basel), 2021. 13(9).","DOI":"10.3390\/cancers13092196"},{"key":"2276_CR44","doi-asserted-by":"crossref","unstructured":"Insua-Rodriguez J et al. Stress signaling in breast cancer cells induces matrix components that promote chemoresistant metastasis. EMBO Mol Med, 2018. 10(10).","DOI":"10.15252\/emmm.201809003"},{"issue":"4","key":"2276_CR45","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4161\/cc.27379","volume":"13","author":"MP Lisanti","year":"2014","unstructured":"Lisanti MP, et al. JNK1 stress signaling is hyper-activated in high breast density and the tumor stroma: connecting fibrosis, inflammation, and stemness for cancer prevention. Cell Cycle. 2014;13(4):580\u201399.","journal-title":"Cell Cycle"},{"key":"2276_CR46","doi-asserted-by":"crossref","unstructured":"Lipner MB et al. Irreversible JNK1-JUN Inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU\/FOLFOX chemotherapy. JCI Insight, 2020. 5(8).","DOI":"10.1172\/jci.insight.129905"},{"issue":"12","key":"2276_CR47","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1172\/JCI75661","volume":"124","author":"TU Barbie","year":"2014","unstructured":"Barbie TU, et al. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest. 2014;124(12):5411\u201323.","journal-title":"J Clin Invest"},{"issue":"8","key":"2276_CR48","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/s41418-022-00940-1","volume":"29","author":"W Xie","year":"2022","unstructured":"Xie W, et al. IKBKE phosphorylates and stabilizes snail to promote breast cancer invasion and metastasis. Cell Death Differ. 2022;29(8):1528\u201340.","journal-title":"Cell Death Differ"},{"issue":"29","key":"2276_CR49","doi-asserted-by":"publisher","first-page":"eabb0616","DOI":"10.1126\/sciadv.abb0616","volume":"6","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, et al. Co-delivery of IKBKE SiRNA and Cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer. Sci Adv. 2020;6(29):eabb0616.","journal-title":"Sci Adv"},{"issue":"8","key":"2276_CR50","doi-asserted-by":"publisher","first-page":"e3022","DOI":"10.1038\/cddis.2017.396","volume":"8","author":"Y Liu","year":"2017","unstructured":"Liu Y, et al. Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines. Cell Death Dis. 2017;8(8):e3022.","journal-title":"Cell Death Dis"},{"key":"2276_CR51","doi-asserted-by":"crossref","unstructured":"M\u00f6ller M et al. The specific IKK\u03b5\/TBK1 inhibitor amlexanox suppresses human melanoma by the Inhibition of autophagy, NF-\u03baB and MAP kinase pathways. Int J Mol Sci, 2020. 21(13).","DOI":"10.3390\/ijms21134721"},{"issue":"17","key":"2276_CR52","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.7150\/thno.26687","volume":"8","author":"C Cheng","year":"2018","unstructured":"Cheng C, et al. Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKK\u025b\/TBK1\/NF-\u03baB signaling. Theranostics. 2018;8(17):4633\u201348.","journal-title":"Theranostics"},{"issue":"1","key":"2276_CR53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.7150\/ijbs.100212","volume":"21","author":"J Shin","year":"2025","unstructured":"Shin J, et al. TBK1 inhibitor amlexanox exerts anti-cancer effects against endometrial cancer by regulating AKT\/NF-kappaB signaling. Int J Biol Sci. 2025;21(1):143\u201359.","journal-title":"Int J Biol Sci"},{"key":"2276_CR54","doi-asserted-by":"publisher","first-page":"114895","DOI":"10.1016\/j.bcp.2021.114895","volume":"197","author":"C Bailly","year":"2022","unstructured":"Bailly C. The potential value of amlexanox in the treatment of cancer: molecular targets and therapeutic perspectives. Biochem Pharmacol. 2022;197:114895.","journal-title":"Biochem Pharmacol"},{"issue":"62","key":"2276_CR55","doi-asserted-by":"publisher","first-page":"104894","DOI":"10.18632\/oncotarget.20581","volume":"8","author":"ND Ebelt","year":"2017","unstructured":"Ebelt ND, et al. A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib. Oncotarget. 2017;8(62):104894\u2013912.","journal-title":"Oncotarget"},{"issue":"1","key":"2276_CR56","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/1078-0432.CCR-09-1180","volume":"16","author":"P Vivas-Mejia","year":"2010","unstructured":"Vivas-Mejia P, et al. c-Jun-NH2-kinase-1 Inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 2010;16(1):184\u201394.","journal-title":"Clin Cancer Res"},{"key":"2276_CR57","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0091-679X(07)83023-8","volume":"83","author":"KR Johnson","year":"2007","unstructured":"Johnson KR, Leight JL, Weaver VM. Demystifying the effects of a three-dimensional microenvironment in tissue morphogenesis. Methods Cell Biol. 2007;83:547\u201383.","journal-title":"Methods Cell Biol"},{"issue":"1","key":"2276_CR58","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118\u201327.","journal-title":"Biostatistics"},{"issue":"2","key":"2276_CR59","doi-asserted-by":"publisher","first-page":"e17238","DOI":"10.1371\/journal.pone.0017238","volume":"6","author":"C Chen","year":"2011","unstructured":"Chen C, et al. Removing batch effects in analysis of expression microarray data: an evaluation of six batch adjustment methods. PLoS ONE. 2011;6(2):e17238.","journal-title":"PLoS ONE"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02276-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02276-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02276-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T17:02:16Z","timestamp":1749056536000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-025-02276-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2276"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02276-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.04.16.649065","asserted-by":"object"}]},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"269"}}